Project: HeartPace: Engineering the first biological Pacemaker for bradycardia patients

Acronym HeartPace (Reference Number: 114245)
Duration 01/11/2020 - 01/11/2023
Project Topic HeartPace will deliver the first-ever biological pacemaker platform, based on adenoviral gene therapy, providing an improved alternative over electronic devices to treat bradycardia. To achieve this goal, we will develop a suite of novel technologies that can permanently restore and regenerate natural cardiac pacing. By the end of the project, we will provide i) a short-term pacemaker gene therapy ready to enter pre-CTA/IMPD studies and ii) proof-of-concept for long-term pacemaker gene therapy.
Network Eurostars 2
Call Eurostars Cut–off 13

Project partner

Number Name Role Country
1 Academic Medical Center Amsterdam, part of Amsterdam UMC Partner Netherlands
2 Naason Science Inc. Partner Korea, Republic of
3 PacingCure B.V. Coordinator Netherlands
4 SIRION Biotech GmbH Partner Germany
5 Witten/Herdecke University Partner Germany